<DOC>
	<DOCNO>NCT02226939</DOCNO>
	<brief_summary>Study assess antiviral efficacy , pharmacokinetics , tolerability 200 mg BILN 2061 ZW polyethylene glycol 400 ( PEG 400 : ethanol ) drinking solution give orally two day bid patient cirrhosis chronic Hepatitis C Virus ( HCV ) infection</brief_summary>
	<brief_title>Antiviral Efficacy , Pharmacokinetics Safety BILN 2061 ZW Patients With Cirrhosis Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Female male sex , age 18 year old Chronic Hepatitis C virus ( HCV ) infection Liver biopsy consistent active HCV infection obtain within last 36 month . No previous clinical evidence decompensated cirrhosis . Present cirrhosis status consistent grade A , accord ChildTurcottePugh classification , confirm screen No evidence significant gastroesophageal varix ( &gt; grade 1 risk factor ) accord fiberoptic endoscopy perform within last 12 month No evidence Hepatocellular carcinoma ( HCC ) ultrasound perform screen Written informed consent consistent International Committee Harmonization ( ICH ) / Good Clinical Practice ( GCP ) local legislation give prior study procedure HCV genotype I HCV load great 50,000 copy messenger ribonucleic acid ( mRNA ) per ml serum screen Women childbearing potential breastfeeding woman . Postmenopausal woman less 6 month last menses , surgically sterilize hysterectomised less 3 month operation negative serum pregnancy test Males use adequate form contraception ( condom , sterilization least 6 month post operation ) case partner childbearing potential ( criterion see ) use adequate form contraception ( hormonal contraceptive , oral injectable/ implantable , intrauterine device ( IUD ) ) Any additional plausible cause chronic liver disease , include presence virus know suspected cause hepatitis Evidence gastroesophageal varix Any histological evidence hepatocytic dysplasia Following serological constellation : Hepatitis B surface ( HBs ) Ag positive OR antiHepatitis B core ( HBc ) positive anti HBs negative OR antiHAV IgM positive OR antiHuman immunodeficiency Virus ( HIV ) positive History abuse alcohol within past twelve month Planned concurrent usage pharmacological therapy screening , include antiviral therapy Any concurrent infectious disease require antimicrobial treatment History malignancy ( except previously cure squamous cell basal cell carcinoma skin ) Usage investigational drug within thirty ( 30 ) day prior enrolment ; plan usage investigational drug course current study Known hypersensitivity drug Inability comply protocol Prior present ChildÂ´s B C liver diseases Bilirubin refer follow exclusion criterion Prothrombin time &lt; 70 % Albumin &lt; 3.5 g/dl Clinical evidence ascites Clinical evidence encephalopathy Clinically apparent jaundice total bilirubin alkaline phosphatase exceed 2.0 x upper limit normal ( ULN ) screen ALT AST &gt; = 10 x ULN screen A platelet count le 80.000 platelet per mm3 screen White blood cell count le 2,000 cell per mm3 screen AFP &gt; 100 ng/ml Splenectomy Positive test illicit unprescribed drug medication screen . Positive test cannabis may allow investigator ass result clinically significant Patients clinically significant laboratory abnormality base investigator 's medical assessment screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>